Doron Efrat is an American entrepreneur and nutraceutical industry figure best known as the founder and President of Mega Resveratrol, a U.S.-based company specializing in pharmaceutical-grade trans-resveratrol supplements. His work sits at the intersection of personal health advocacy and applied nutritional science, and he is credited with elevating the quality standards applied to resveratrol supplementation in the consumer health market.
Early Life and Personal Health Background
Efrat’s professional trajectory in the nutraceutical space was significantly shaped by a personal medical event. In 2003, he experienced a heart attack that led to a diagnosis of elevated Lipoprotein(a), a lipid particle associated with an increased risk of cardiovascular disease and one that does not respond to conventional cholesterol-lowering interventions in the way that standard LDL cholesterol does. Faced with limited pharmacological options and motivated to address the condition through evidence-informed lifestyle and supplement-based strategies, Efrat began researching naturally occurring compounds with cardiovascular and antioxidant properties.
His investigation led him to trans-resveratrol, a polyphenol found naturally in red grape skin, Japanese knotweed, and several other plant sources, which had attracted growing scientific interest for its potential antioxidant, anti-inflammatory, and cardioprotective effects.
Founding of Mega Resveratrol
In 2007, Efrat founded Mega Resveratrol under the parent company Candlewood Stars Inc., headquartered in Danbury, Connecticut. His founding vision was to produce a trans-resveratrol supplement that met pharmaceutical-grade standards of purity and potency, differentiating the product from the broader dietary supplement market, which at the time offered few independently verified, high-purity options.
To achieve this, Efrat collaborated with U.S.-based laboratories for independent third-party testing and incorporated micronization technology into the manufacturing process. Micronization involves reducing particles to under two microns in size, a technique that significantly improves the surface area and absorption of active compounds in the gastrointestinal tract. The resulting product was reported to achieve bioavailability up to 1,000% greater than standard non-micronized trans-resveratrol formulations.
Leadership and Industry Impact
As President of Mega Resveratrol, Efrat has overseen the company’s growth from a niche supplement brand into a globally recognized supplier of pharmaceutical-grade resveratrol. The company’s products are used by integrative medicine practitioners and researchers in the United States and internationally.
Efrat’s approach to product development has been consistently guided by scientific credibility and manufacturing transparency. Under his leadership, Mega Resveratrol has maintained a product line free of additives, fillers, and preservatives, with all formulations produced in GMP-compliant facilities and verified through independent laboratory testing.
His personal story, from cardiac patient to nutraceutical entrepreneur, has made him a recognizable voice in health and wellness communities that intersect conventional medicine with evidence-based supplementation. Efrat continues to lead Mega Resveratrol as of the company’s most recent public records.
